Nektar Therapeutics (0UNL.L)
USD 0.84
(0.63%)
USD 0.84
(0.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -137.42 Million USD | 42.8% |
| 2022 | -240.23 Million USD | 46.15% |
| 2021 | -446.1 Million USD | -17.42% |
| 2020 | -379.92 Million USD | 13.66% |
| 2019 | -440.03 Million USD | -163.96% |
| 2018 | 687.93 Million USD | 1253.44% |
| 2017 | -59.64 Million USD | 47.15% |
| 2016 | -112.85 Million USD | -284.24% |
| 2015 | -29.37 Million USD | -78.17% |
| 2014 | -16.48 Million USD | 86.28% |
| 2013 | -120.13 Million USD | 14.92% |
| 2012 | -141.2 Million USD | -13.93% |
| 2011 | -123.93 Million USD | -338.64% |
| 2010 | -28.25 Million USD | 70.3% |
| 2009 | -95.13 Million USD | -15.1% |
| 2008 | -82.65 Million USD | -128.65% |
| 2007 | -36.14 Million USD | 77.3% |
| 2006 | -159.23 Million USD | 12.81% |
| 2005 | -182.63 Million USD | -146.99% |
| 2004 | -73.94 Million USD | -11.72% |
| 2003 | -66.18 Million USD | 33.87% |
| 2002 | -100.08 Million USD | 61.05% |
| 2001 | -256.96 Million USD | -288.52% |
| 2000 | -66.13 Million USD | -63.37% |
| 1999 | -40.48 Million USD | -84.1% |
| 1998 | -21.99 Million USD | -60.23% |
| 1997 | -13.72 Million USD | -19.34% |
| 1996 | -11.5 Million USD | -30.68% |
| 1995 | -8.8 Million USD | -54.39% |
| 1994 | -5.7 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -36.48 Million USD | -5.9% |
| 2024 Q1 | -34.45 Million USD | -12.37% |
| 2023 FY | -137.42 Million USD | 42.8% |
| 2023 Q1 | -37.01 Million USD | 9.47% |
| 2023 Q2 | -50.59 Million USD | -36.69% |
| 2023 Q3 | -44.86 Million USD | 11.33% |
| 2023 Q4 | -30.66 Million USD | 31.66% |
| 2022 Q2 | -46.79 Million USD | 59.34% |
| 2022 Q1 | -115.08 Million USD | -1.93% |
| 2022 FY | -240.23 Million USD | 46.15% |
| 2022 Q4 | -40.88 Million USD | -9.12% |
| 2022 Q3 | -37.47 Million USD | 19.92% |
| 2021 Q1 | -109.39 Million USD | 1.2% |
| 2021 Q2 | -110.2 Million USD | -0.74% |
| 2021 FY | -446.1 Million USD | -17.42% |
| 2021 Q3 | -113.59 Million USD | -3.08% |
| 2021 Q4 | -112.91 Million USD | 0.6% |
| 2020 Q3 | -103.05 Million USD | -32.61% |
| 2020 Q2 | -77.7 Million USD | 41.85% |
| 2020 FY | -379.92 Million USD | 13.66% |
| 2020 Q4 | -110.72 Million USD | -7.44% |
| 2020 Q1 | -133.63 Million USD | -21.88% |
| 2019 Q3 | -98.74 Million USD | 11.02% |
| 2019 Q1 | -120.68 Million USD | -20.33% |
| 2019 FY | -440.03 Million USD | -163.96% |
| 2019 Q4 | -109.63 Million USD | -11.04% |
| 2019 Q2 | -110.97 Million USD | 8.05% |
| 2018 Q4 | -100.29 Million USD | -1.68% |
| 2018 Q3 | -98.63 Million USD | -110.13% |
| 2018 FY | 687.93 Million USD | 1253.44% |
| 2018 Q2 | 973.6 Million USD | 1222.45% |
| 2018 Q1 | -86.73 Million USD | -260.9% |
| 2017 Q3 | 69.48 Million USD | 237.17% |
| 2017 Q1 | -54.43 Million USD | -69.35% |
| 2017 Q2 | -50.65 Million USD | 6.95% |
| 2017 Q4 | -24.03 Million USD | -134.59% |
| 2017 FY | -59.64 Million USD | 47.15% |
| 2016 Q4 | -32.14 Million USD | 2.3% |
| 2016 FY | -112.85 Million USD | -284.24% |
| 2016 Q2 | -38.32 Million USD | -304.1% |
| 2016 Q1 | -9.48 Million USD | 67.7% |
| 2016 Q3 | -32.9 Million USD | 14.15% |
| 2015 Q3 | 419 Thousand USD | 100.96% |
| 2015 FY | -29.37 Million USD | -78.17% |
| 2015 Q2 | -43.46 Million USD | -200.99% |
| 2015 Q1 | 43.04 Million USD | 214.82% |
| 2015 Q4 | -29.36 Million USD | -7108.11% |
| 2014 Q1 | -36.4 Million USD | -1.42% |
| 2014 Q2 | -22.91 Million USD | 37.05% |
| 2014 Q3 | 80.32 Million USD | 450.5% |
| 2014 Q4 | -37.48 Million USD | -146.67% |
| 2014 FY | -16.48 Million USD | 86.28% |
| 2013 Q1 | -45.4 Million USD | -4.66% |
| 2013 FY | -120.13 Million USD | 14.92% |
| 2013 Q4 | -35.89 Million USD | -450.1% |
| 2013 Q3 | -6.52 Million USD | 79.99% |
| 2013 Q2 | -32.6 Million USD | 28.19% |
| 2012 Q3 | -32.9 Million USD | -21.91% |
| 2012 Q4 | -43.38 Million USD | -31.86% |
| 2012 Q1 | -37.93 Million USD | -10.05% |
| 2012 Q2 | -26.98 Million USD | 28.85% |
| 2012 FY | -141.2 Million USD | -13.93% |
| 2011 Q2 | -34.26 Million USD | -1.17% |
| 2011 FY | -123.93 Million USD | -338.64% |
| 2011 Q4 | -34.46 Million USD | -61.53% |
| 2011 Q3 | -21.33 Million USD | 37.72% |
| 2011 Q1 | -33.86 Million USD | -64.89% |
| 2010 Q4 | -20.53 Million USD | -229.94% |
| 2010 Q1 | -3.35 Million USD | 38.89% |
| 2010 FY | -28.25 Million USD | 70.3% |
| 2010 Q2 | 1.86 Million USD | 155.6% |
| 2010 Q3 | -6.22 Million USD | -433.42% |
| 2009 Q1 | -30.29 Million USD | -211.57% |
| 2009 Q4 | -5.49 Million USD | 80.96% |
| 2009 Q3 | -28.85 Million USD | 5.32% |
| 2009 FY | -95.13 Million USD | -15.1% |
| 2009 Q2 | -30.48 Million USD | -0.6% |
| 2008 Q1 | -41.88 Million USD | -212.06% |
| 2008 FY | -82.65 Million USD | -128.65% |
| 2008 Q4 | 27.15 Million USD | 178.57% |
| 2008 Q3 | -34.56 Million USD | -3.61% |
| 2008 Q2 | -33.35 Million USD | 20.37% |
| 2007 Q1 | -25.96 Million USD | 35.34% |
| 2007 FY | -36.14 Million USD | 77.3% |
| 2007 Q4 | 37.38 Million USD | 290.99% |
| 2007 Q3 | -19.57 Million USD | 30.07% |
| 2007 Q2 | -27.98 Million USD | -7.77% |
| 2006 FY | -159.23 Million USD | 12.81% |
| 2006 Q1 | -33.17 Million USD | 69.49% |
| 2006 Q2 | -63.21 Million USD | -90.55% |
| 2006 Q4 | -40.16 Million USD | -77.07% |
| 2006 Q3 | -22.68 Million USD | 64.12% |
| 2005 FY | -182.63 Million USD | -146.99% |
| 2005 Q4 | -108.72 Million USD | -365.29% |
| 2005 Q2 | -26.45 Million USD | -9.79% |
| 2005 Q1 | -24.09 Million USD | -36.42% |
| 2005 Q3 | -23.36 Million USD | 11.66% |
| 2004 Q2 | -21.11 Million USD | -30.93% |
| 2004 Q3 | -19.03 Million USD | 9.85% |
| 2004 FY | -73.94 Million USD | -11.72% |
| 2004 Q4 | -17.66 Million USD | 7.23% |
| 2004 Q1 | -16.12 Million USD | 18.99% |
| 2003 Q3 | -14.13 Million USD | 3.22% |
| 2003 Q2 | -14.6 Million USD | 16.74% |
| 2003 FY | -66.18 Million USD | 33.87% |
| 2003 Q4 | -19.9 Million USD | -40.87% |
| 2003 Q1 | -17.54 Million USD | 40.02% |
| 2002 FY | -100.08 Million USD | 61.05% |
| 2002 Q4 | -29.24 Million USD | -18.96% |
| 2002 Q3 | -24.58 Million USD | -8.41% |
| 2002 Q2 | -22.67 Million USD | 3.83% |
| 2002 Q1 | -23.57 Million USD | 28.12% |
| 2001 Q3 | -28.49 Million USD | 74.04% |
| 2001 Q1 | -85.93 Million USD | -381.76% |
| 2001 FY | -256.96 Million USD | -288.52% |
| 2001 Q2 | -109.73 Million USD | -27.7% |
| 2001 Q4 | -32.8 Million USD | -15.14% |
| 2000 Q1 | -14.77 Million USD | 26.08% |
| 2000 FY | -66.13 Million USD | -63.37% |
| 2000 Q3 | -15.93 Million USD | 9.41% |
| 2000 Q4 | -17.83 Million USD | -11.91% |
| 2000 Q2 | -17.59 Million USD | -19.11% |
| 1999 Q4 | -19.98 Million USD | -161.78% |
| 1999 Q3 | -7.63 Million USD | -14.45% |
| 1999 FY | -40.48 Million USD | -84.1% |
| 1999 Q2 | -6.66 Million USD | -7.56% |
| 1999 Q1 | -6.2 Million USD | 9.42% |
| 1998 Q4 | -6.84 Million USD | -16.47% |
| 1998 Q3 | -5.87 Million USD | -47.26% |
| 1998 Q2 | -3.99 Million USD | 24.37% |
| 1998 FY | -21.99 Million USD | -60.23% |
| 1998 Q1 | -5.27 Million USD | -22.75% |
| 1997 Q1 | -2.74 Million USD | 27.79% |
| 1997 Q3 | -3.46 Million USD | -8.63% |
| 1997 Q4 | -4.29 Million USD | -24.14% |
| 1997 FY | -13.72 Million USD | -19.34% |
| 1997 Q2 | -3.18 Million USD | -16.18% |
| 1996 Q3 | -2.7 Million USD | 10.0% |
| 1996 Q4 | -3.8 Million USD | -40.74% |
| 1996 Q1 | -2.1 Million USD | 16.0% |
| 1996 FY | -11.5 Million USD | -30.68% |
| 1996 Q2 | -3 Million USD | -42.86% |
| 1995 Q1 | -2.3 Million USD | 4.17% |
| 1995 Q2 | -2 Million USD | 13.04% |
| 1995 Q4 | -2.5 Million USD | -25.0% |
| 1995 Q3 | -2 Million USD | 0.0% |
| 1995 FY | -8.8 Million USD | -54.39% |
| 1994 Q1 | -1 Million USD | 0.0% |
| 1994 FY | -5.7 Million USD | 0.0% |
| 1994 Q4 | -2.4 Million USD | -118.18% |
| 1994 Q2 | -1.1 Million USD | -10.0% |
| 1994 Q3 | -1.1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 102.004% |
| Dynavax Technologies Corporation | -37.02 Million USD | -271.138% |
| Illumina, Inc. | -1.06 Billion USD | 87.145% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 106.951% |
| Biogen Inc. | 1.29 Billion USD | 110.597% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 70.161% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 112.639% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 48.688% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -2508.18% |
| Waters Corporation | 817.67 Million USD | 116.807% |
| Perrigo Company plc | 151.9 Million USD | 190.471% |
| uniQure N.V. | -282.87 Million USD | 51.418% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 64.897% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -86.988% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 50.209% |
| bluebird bio, Inc. | -244.26 Million USD | 43.739% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -13.112% |
| Imunon, Inc. | -21.03 Million USD | -553.458% |
| Myriad Genetics, Inc. | -123.7 Million USD | -11.095% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 154.773% |
| Editas Medicine, Inc. | -169.18 Million USD | 18.77% |
| Verastem, Inc. | -92.08 Million USD | -49.239% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.024% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -204.865% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -24.237% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -207.666% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 170.677% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 49.846% |
| Evolus, Inc. | -49.23 Million USD | -179.132% |
| Adicet Bio, Inc. | -152.03 Million USD | 9.611% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -41.156% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 103.396% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 11.66% |
| FibroGen, Inc. | -281.81 Million USD | 51.236% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 110.18% |
| OPKO Health, Inc. | -157.02 Million USD | 12.48% |
| Homology Medicines, Inc. | -48.25 Million USD | -184.789% |
| Geron Corporation | -193.94 Million USD | 29.142% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 51.298% |
| Exelixis, Inc. | 170.88 Million USD | 180.42% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -36.298% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -146.476% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 73.331% |
| Zoetis Inc. | 3.06 Billion USD | 104.478% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 40.72% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -185.114% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 103.19% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -250.995% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 61.15% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 228.097% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 140.71% |
| Blueprint Medicines Corporation | -486.27 Million USD | 71.739% |
| Insmed Incorporated | -709.62 Million USD | 80.634% |
| TG Therapeutics, Inc. | 20.63 Million USD | 766.045% |
| Incyte Corporation | 620.52 Million USD | 122.147% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 81.081% |